Dr. A. Raj Kumar

• Dr. A. Rajkumar is a Senior Consultant Medical Oncologist with more than 25 years of experience in the field of Oncology. He completed his MBBS from Coimbatore Medical College, MD in Radiotherapy from Madras Medical College, and DM in Medical Oncology from Madras Medical College. He also holds a PG Diploma in Clinical Trials from the London School of Hygiene & Tropical Medicine, University of London, UK.
• He has held key leadership positions including Head of the Department of Medical Oncology and Chairman of the Oncology Division at GKNM Hospital, Coimbatore. Dr. Rajkumar has extensive experience in the treatment of breast cancer, genitourinary cancers, head and neck cancers, and other solid tumors. His key area of expertise is in the treatment of breast cancers for which he has been the Lead Physician of the multi disciplinary team for the past two decades. 
• He has actively participated in several national and international clinical trials and has authored multiple scientific publications in reputed peer-reviewed journals, including The Lancet Oncology. He has presented research papers at various national and international oncology conferences and has received awards for his scientific contributions and distinguished service in Oncology.

  • Breast Cancer 

  • Head & Neck Cancers 

  • Genitourinary Cancers [ Prostate, Bladder, Kidneys, Testis]  

  • Clinical Trials & Research 

• Best Scientific Paper award at the XIV Annual conference of UP Chapter of Association of Radiation Oncologists of India (AROI), Lucknow,2001.

• J.M. Pinto Memorial Award for the Best Paper, 23rd Annual National Conference of Association of Radiation Oncologists of India (AROI), Chandigarh, 2001. 

• Distinguished Service Award, G. Kuppuswamy Naidu Memorial Hospital, Coimbatore,2018

• Publications in national and international peer-reviewed journals including The Lancet Oncology 

• Presenter at national and international oncology conferences including ESMO and Asia Pacific Breast Cancer Summit 

• Icon of Coimbatore Award in the field of health care, Rathinam College [ 2019 ]

• Concurrent chemoradiation in head and neck cancers (2000). This is a prospective study spanning two years. This study was submitted as a dissertation to the TN Dr. MGR Medical University as a mandatory requirement of my residency training in Radiation Oncology.
• Utility and feasibility of anato-metabolic imaging in brain tumors. This was a prospective study done during my senior residency under the guidance of Dr.N.R. Datta, Professor of Radiation Oncology, SGPGIMS, Lucknow. This paper was presented at the Annual conference of UP Chapter of Association of Radiation Oncologists of India (AROI), Lucknow, 2001.
• Prevalence of Helicobacter pylori in patients with carcinoma stomach- Our Experience. This was a prospective study done during my senior residency in Medical Oncology that analysed the prevalence of H.pylori among patients with carcinoma stomach at Madras Medical College. This paper was presented at the XI Biennial Conference of Indian Society of Oncology and XIII Biennial Conference of Indian Society of Medical & Pediatric Oncology at Bangalore 2004.

• A mutinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Drug X in the prevention of venous thromboembolism in cancer patients at high risk for VTE and who are undergoing chemotherapy.
• A study of Drug X in Combination with Paclitaxel plus Cisplatin in Advanced NSCLC
• Phase II single-arm study of Drug X by 4-hr infusion in patients with recurring platinum-resistant ovarian cancer
• A randomised phase II study comparing Drug X-pemetrexed, pemetrexed alone and Drug X alone as second line treatment for non-smoker patients with locally advanced or metastatic NSCLC
• A Multinational, Randomized, double blind, placebo controlled study to evaluate the efficacy and safety of xxxxxx in the prevention of Venous Thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy (protocol EFC6521)
• A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of Drug X 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients with Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
• Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + Drug X versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously untreated for metastatic disease
• A phase III study of Erbb2 Positive Advanced or Metastatic Gastric or Esophageal or Gastroesophageal junction adenocarcinoma treated with capecitabine plus Oxaliplatin with or without Drug X
• Prospective, multi-centric, randomized open-label, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-033/ERBITUX in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
• MYL-Her3001-A multicenter, double-blind, randomized, parallel-group, phase III study of the efficacy and safety of Hercules plus taxane versus Herceptin plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.
• A Prospective, Multicenter, Observational Study Examining The clinical Utility Of Canscript In Routine Clinical Practice".

• A mutinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Drug X in the prevention of venous thromboembolism in cancer patients at high risk for VTE and who are undergoing chemotherapy.
• A study of Drug X in Combination with Paclitaxel plus Cisplatin in Advanced NSCLC
• Phase II single-arm study of Drug X by 4-hr infusion in patients with recurring platinum-resistant ovarian cancer
• A randomised phase II study comparing Drug X-pemetrexed, pemetrexed alone and Drug X alone as second line treatment for non-smoker patients with locally advanced or metastatic NSCLC
• A Multinational, Randomized, double blind, placebo controlled study to evaluate the efficacy and safety of xxxxxx in the prevention of Venous Thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy (protocol EFC6521)
• A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of Drug X 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients with Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
• Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + Drug X versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously untreated for metastatic disease
• A phase III study of Erbb2 Positive Advanced or Metastatic Gastric or Esophageal or Gastroesophageal junction adenocarcinoma treated with capecitabine plus Oxaliplatin with or without Drug X
• Prospective, multi-centric, randomized open-label, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-033/ERBITUX in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
• MYL-Her3001-A multicenter, double-blind, randomized, parallel-group, phase III study of the efficacy and safety of Hercules plus taxane versus Herceptin plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.
• A Prospective, Multicenter, Observational Study Examining The clinical Utility Of Canscript In Routine Clinical Practice".